We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
33 result(s) found, displaying 1 to 10
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CAPTOPRIL - REACH captopril 5 mg/mL oral solution bottle.
-
Prescription medicine registrationActive ingredients: captopril.
-
Australian public assessment report (AusPar)Dexrazoxane-Reach is indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin therapy to maintain tumour control.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for DEXRAZOXANE-REACH dexrazoxane 250 mg powder for injection for infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for DEXRAZOXANE-REACH dexrazoxane 500 mg powder for injection for infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for FUROSEMIDE-REACH furosemide 20 mg/2 mL solution for injection ampoule.
-
Prescription medicine registrationActive ingredients: dexrazoxane.
-
Mar-2025Prescription medicine evaluationActive ingredient: sodium oxybate.
-
Prescription medicine registrationActive ingredients: furosemide.
-